ArticleAntibody therapeutics2026
Application of a novel LC-MS-based proteomic workflow for host cell protein monitoring and risk control in biotherapeutics.
Article in Antibody therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comprehensive monitoring of host cell proteins (HCPs) is essential for ensuring the quality, safety, and consistency of antibody therapeutics. Conventional enzyme-linked immunosorbent assay-based assays provide only total HCP burden and lack the resolution to identify individual, functionally active impurities that may affect product stability or efficacy. To address this limitation, we developed a versatile, high-sensitivity mass spectrometry-based workflow capable of molecular-level HCP characterization and risk assessment. Methods: We developed and evaluated a sub-ppm, easy-to-use liquid chromatography-mass spectrometry-based proteomics workflow for the identification and relative quantitation of HCPs across downstream purification and final formulation, which offers molecular-specific, risk-based process characterization and regulatory-aligned quality assurance for antibody therapeutics. Results: The workflow demonstrated sub-ppm sensitivity and excellent reproducibility, enabling comprehensive tracking of HCP clearance across the purification process. Scale-up from 100 to 500 L led to higher total HCP levels and moderately increased species diversity, indicating reduced clearance efficiency and altered impurity profiles. Mechanistic interpretation linked transient thioredoxin and thioredoxin reductase presence to disulfide bond reduction and nonreducing capillary electrophoresis-sodium dodecyl sulfate purity fluctuations. In the formulation stage, lipoprotein lipase was identified as a key contributor to polysorbate 80 (PS80) degradation, consistent with accelerated stability results, leading to successful process optimization. Conclusions: This study establishes a comprehensive, sub-ppm data-independent acquisition (DIA)-mass spectrometry (MS) platform for HCP monitoring in antibody therapeutics, bridging analytical characterization with process and formulation control. The workflow enables molecular-level understanding of impurity behavior, supports proactive risk mitigation, and enhances overall process consistency, representing a significant advancement in HCP management and biotherapeutic quality assurance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.